MIRM vs. ICPT, UROV, CDMO, NGM, DRRX, ALPN, NUVL, ALKS, PRGO, and CRNX
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Urovant Sciences (UROV), Avid Bioservices (CDMO), NGM Biopharmaceuticals (NGM), DURECT (DRRX), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Intercept Pharmaceuticals (NASDAQ:ICPT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
Intercept Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 0 mentions for Intercept Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.30 beat Intercept Pharmaceuticals' score of 0.13 indicating that Intercept Pharmaceuticals is being referred to more favorably in the media.
Intercept Pharmaceuticals has a net margin of -19.39% compared to Intercept Pharmaceuticals' net margin of -69.67%. Intercept Pharmaceuticals' return on equity of -56.46% beat Mirum Pharmaceuticals' return on equity.
Intercept Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Intercept Pharmaceuticals currently has a consensus price target of $19.00, indicating a potential upside of 0.00%. Mirum Pharmaceuticals has a consensus price target of $49.73, indicating a potential upside of 98.35%. Given Intercept Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Intercept Pharmaceuticals.
Intercept Pharmaceuticals received 955 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 72.55% of users gave Mirum Pharmaceuticals an outperform vote while only 72.27% of users gave Intercept Pharmaceuticals an outperform vote.
83.8% of Intercept Pharmaceuticals shares are held by institutional investors. 6.2% of Intercept Pharmaceuticals shares are held by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Mirum Pharmaceuticals beats Intercept Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Mirum Pharmaceuticals Competitors List
Related Companies and Tools